ERBB2 and lung carcinoma: T-DXd exhibited superior efficacy in not only HER2-positive breast cancers [10,11] but also HER2-low (IHC 1+ or IHC 2+/ISH-non-amplified) advanced breast cancers [12] and HER2-mutant lung cancers [13].